Treatment Innovations in Relapsed/Refractory Marginal Zone Lymphoma

Expert panelists review the pathophysiology of marginal zone lymphoma and reflect on its prevalence as a rare disease.

Shared insight on treating marginal zone lymphoma with the current treatment armamentarium.

Following discussion on the NCCN guidelines for second-line therapy in marginal zone lymphoma, experts highlight approved treatment options.

A broad review of BTK inhibition as a novel therapeutic approach toward the treatment of marginal zone lymphoma.

Expert perspectives on the MAGNOLIA trial and novel BTK inhibitor zanubrutinib in the context of marginal zone lymphoma treatment.

Panelists look at the class effects of BTK inhibitors and share optimal strategies to select therapy and manage toxicities.

Moving beyond BTK inhibition in marginal zone lymphoma, expert panelists review other therapies and drug classes with indications in this setting.

Closing out their discussion on marginal zone lymphoma, the panel considers which future treatment strategies are most promising.